Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion
•is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major player in infec...
•The agreements with Curevo, LimmaTech Biologics and Vaccine Company give Lilly access to novel technology and experimental immunizations for shingles, common bacterial pathogens and Epstein-Barr virus...
•“These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Dan Skovronsky, Lilly’s chief scientific and product officer, said in a statemen...
هذا الخبر من Bloomberg. خبر يقدم أدوات ذكاء اصطناعي للتلخيص والترجمة والاستماع.
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major player in infectious diseases. The agreements with Curevo, LimmaTech Biologics and Vaccine Company give Lilly access to novel technology and experimental immunizations for shingles, common bacterial pathogens and Epstein-Barr virus, according to a statement on Tuesday. “These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Dan Skovronsky, Lilly’s chief scientific and product officer, said in a statement. Bloomberg News Health Reporter, Madison Muller, joins Paul Sweeney and Alexis Christoforous on "Bloomberg Intelligence" to analyze what's next for Eli Lilly after agreeing to buy three vaccine developers. (Source: Bloomberg)المصدر: Bloomberg | Source: Bloomberg
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة Bloomberg. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by Bloomberg. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
